Aquestive Therapeutics rises after $85 million stock sale

Drugmaker Aquestive Therapeutics' AQST.O shares rise 5.4% to $4.23

AQST announces pricing of $85 million stock offering

Co sold ~21.3 million shares at $4 apiece, just 0.2% discount to stock's last close

Proceeds will be used to advance the launch and commercialization of epinephrine sublingual film for the treatment of severe, life-threatening allergic reactions and other purposes

Offering led by RTW Investments and included participation from Samsara BioCapital, EcoR1 Capital, Perceptive Advisors, Sio Capital Management, ADAR1 Capital Management and Nantahala Capital

Leerink Partners, Cantor, and Oppenheimer were joint bookrunning managers for the offering

All nine brokerages covering the stock rate "buy" or higher; median PT $8 - data compiled by LSEG

As of last close, AQST stock up 12.6% YTD